Weight-loss diabetes medications such as metformin and GLP-1 receptor agonists may exacerbate cancer-associated cachexia and frailty, whereas thiazolidinediones may compound chemotherapy-associated risks for cardiomyopathy and congestive heart failure. The gene discussed is GLP1R; the disease is diabetes mellitus.